Mitigating Cardiovascular Risk Through Effective Lipid Management : Episode 4

Video

April 8, 2022

Residual Cardiovascular Risk

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

EP: 1.The Burden of ASCVD and Evidence-Based Guidelines

EP: 2.A Patient’s Post-MI Journey

EP: 3.Improving the Care Continuum

EP: 4.Residual Cardiovascular Risk

EP: 5.Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP: 6.Finding the Optimal Statin Dose

EP: 7.Therapy Beyond Statins in the Inpatient Setting

EP: 8.Using Adjunct Therapies in LDL Management

EP: 9.Ensuring Continuity of Care for the ASCVD Patient

EP: 10.Unmet Needs in Lipid Management

EP: 11.Defining “Optimal Care” for ASCVD Within Health Systems

EP: 12.What Does a Multidisciplinary Team Look Like?

EP: 13.The Future of LDL Management for Patients With High-Risk ASCVD

EP: 14.Enhancing Patient Care Through Guideline Adherence

EP: 15.Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP: 16.Appropriate ASCVD Treatment Outside of Closed Health Systems

EP: 17.Utilizing Quality Metrics in ASCVD

EP: 18.Improving Patient and Provider Engagement

EP: 19.Treatment Disparities in the Management of ASCVD

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Dr Elise Tremblay

4 experts in this video

Related Content

AJMC

August 12th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

AJMC podcast banner

August 12th 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Blast cells AML | image credit: Nun22 - stock.adobe.com

August 12th 2025

Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML

August 12th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

Semaglutide injectors and stethoscope | Image credit: Nati – stock.adobe.com

August 12th 2025

Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending

Hayden E. Klein

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

August 12th 2025

5 Hot FDA Approval Dates That Made Waves Across Therapeutic Areas in July

Brooke McCormick

Related Content

AJMC

August 12th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

AJMC podcast banner

August 12th 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Blast cells AML | image credit: Nun22 - stock.adobe.com

August 12th 2025

Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML

August 12th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

Semaglutide injectors and stethoscope | Image credit: Nati – stock.adobe.com

August 12th 2025

Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending

Hayden E. Klein

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

August 12th 2025

5 Hot FDA Approval Dates That Made Waves Across Therapeutic Areas in July

Brooke McCormick

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions